Who is sponsoring NCT05423587?

NCT05423587 is sponsored by Varian, a Siemens Healthineers Company.

What drugs are being tested in NCT05423587?

Interventions in NCT05423587: Genicular Artery Embolisation, Genicular Artery Injection.

What condition does NCT05423587 study?

NCT05423587 studies Knee Osteoarthritis.

Is NCT05423587 still recruiting?

NCT05423587 is currently recruiting now. Last updated 3 December 2024.

Last reviewed 2024-12-03 · How we verify

NCT05423587: GENESISII

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Genicular Artery Embolisation for Knee Osteoarthritis II

Recruiting now NA Last updated 3 December 2024

What this trial tests

NA trial testing Genicular Artery Embolisation in Knee Osteoarthritis in 110 participants. Currently enrolling.

Timeline

30 October 2022

Primary endpoint
31 December 2027

30 June 2028

Quick facts

Lead sponsor	Varian, a Siemens Healthineers Company
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	110
Start date	30 October 2022
Primary completion	31 December 2027
Estimated completion	30 June 2028
Sites	1 location across United Kingdom

Drugs / interventions tested

Genicular Artery Embolisation
Genicular Artery Injection

Conditions studied

Knee Osteoarthritis — all drugs for Knee Osteoarthritis →

Sponsor

Varian, a Siemens Healthineers Company — full company profile →

Who can join

45 and older, any sex, with Knee Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical study is designed as a double-blind sham controlled randomised trial with the option of sham group crossover to receive the GAE treatment at 6 months after unblinding. This study will determine if embolisation of abnormal neovasculature arising from branches of the genicular arteries reduces pain in patients with knee osteoarthritis. The study patient population will consist of up to 110 subjects with knee pain for at least 3 months that is resistant to conservative treatment measures. Subjects will be treated with knee embolisation or 2 mL of saline in the sham arm. At 6 months, all subjects in the sham arm will be allowed to cross-over and receive the embolisation procedure with a follow-up duration of 18 months. The total planned study duration is 3.5 years.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Genicular Artery Embolisation in Patients with Osteoarthritis of the Knee (GENESIS 2): Protocol for a Double-Blind Randomised Sham-Controlled Trial.
Little MW, Harrison R, MacGill S, Speirs A, et al · · 2023 · cited 9× · PMID 37337060 · DOI 10.1007/s00270-023-03477-z
Surgical and nonsurgical treatment of hip and knee osteoarthritis: a 2026 perspective
LAIGAARD J, MALEITZKE T, SKOU S, MECHLENBURG I, et al · · 2026

Verify or expand the search:

Other recruiting trials for Knee Osteoarthritis

Currently open trials in the same condition.

NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
NCT05823727 — Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing Afte · NA · recruiting
NCT07370480 — Knee Osteoarthritis and Thermal Spa Treatment · NA · recruiting
NCT07507175 — Gastrocnemius Myofascial Release in Females With Knee Osteoarthritis · NA · recruiting
NCT07386600 — Dexamethasone vs Dexmedetomidine for iPACK + ACB in TKA · NA · recruiting

Other Varian, a Siemens Healthineers Company trials

Trials by the same sponsor.

NCT06347731 — Varian ProBeam360° Proton Therapy System China Clinical Trial (Wuhan) · NA · completed
NCT05666193 — On-treatment Adaptation of Head and Neck Cancer Dosimetry Plans Using Novel Cone-beam CT and AI-driven Software · NA · completed
NCT05524454 — Evaluation of a Cone-beam CT Scanner for Image Guided Radiotherapy · NA · completed
NCT05524064 — FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases in the Thorax · NA · active not recruiting
NCT05700227 — Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for Muscle-Invasive Bladder Cancer · NA · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05423587 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Varian, a Siemens Healthineers Company
Last refreshed: 3 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05423587.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing